| Literature DB >> 34334979 |
Amit Nakanekar1, Siddharth Kulkarni2, Punam Khobarkar3, Minal Belsare4.
Abstract
Covid 19 pandemic has placed challenges in front of medical health fraternity in terms of management, prevention and immunity building. Effectiveness of any medication has not conclusively proven; hence there is need for integrative management of Covid 19. We have managed a critical case of Covid-19 having history of thalassemia, hypothyroidism with integrative management of Ayurveda and modern medicine. A male patient (59 years of age) with history of thalassemia had complaints of cough and breathlessness since 4 days. He performed RT PCR because of his exposure to a Covid positive cases in immediate family. He was treated with Favipiravir at home for 5 days. He deteriorated on 6th day with SPO2 dropped to 75%, temp raised to 101 F and respiratory rate (RR) raised to 45/min. He was admitted in Yogeshwari Hospital Daund, Maharashtra; treated with oxygen inhalation, Remdesvir and Ayurveda medicines in intensive care unit (ICU). Ayurveda treatment protocol was advised through telemedicine. Significant improvement in clinical symptoms and normal HRCT was observed at completion of treatment. This case report provides further directions for integrative management in cases of Covid 19. Further clinical research studies in this direction are warranted.Entities:
Keywords: Ayurveda; Case report; Covid 19; Critical case; Integrative medicine
Year: 2021 PMID: 34334979 PMCID: PMC8315940 DOI: 10.1016/j.jaim.2021.07.012
Source DB: PubMed Journal: J Ayurveda Integr Med ISSN: 0975-9476
Graph 1Datewise Temp, Pulse, Respiratory rate, blood pressure, SPO2.
Details of Treatment.
| Modern Medicine | Ayurveda medicine | Symptoms | |
|---|---|---|---|
| 28/7/2020 | TAB. Fabiflu 200 9-0-9∗1day 4-0-4∗7day TAB Rebex D 1-0-0 capD3 HD 1-0-0(Once) TAB Vit A 1-0-0 TAB Vit C 500 1-0-1 TAB A-Z Gold 1-0-0 Inj. Clexane 1-0-0 TAB Cettas 200 1-0-1 | Cough | |
| 29/7/2020 | TAB. Fabiflu 200 9-0-9∗1day 4-0-4∗7day TAB Rebex D 1-0-0 CAP.D3 HD 1-0-0(Once) TAB. Vit A 1-0-0 TAB Vit C 500 1-0-1 TAB A-Z Gold 1-0-0 Inj. Clexane 1-0-0 TAB. Cettas 200 1-0-1 | Cough | |
| 30/7/2020 | TAB. Fabiflu 200 9-0-9∗1day 4-0-4∗7day TAB Rebex D 1-0-0 capD3 HD 1-0-0(Once) TAB. Vit A 1-0-0 TAB. Vit C 500 1-0-1 TAB. A-Z Gold 1-0-0 Inj. Clexane 1-0-0 TAB Cettas 200 1-0-1 | Cough | |
| 31/7/2020 | TAB Fabiflu 200 9-0-9∗1day 4-0-4∗7day TAB. Rebex D 1-0-0 CAP.D3 HD 1-0-0(Once) TAB Vit A 1-0-0 TAB Vit C 500 1-0-1 TAB A-Z Gold 1-0-0 Inj. Clexane 1-0-0 TAB. Cettas 200 1-0-1 | Cough | |
| 1/8/2020 | TAB. Fabiflu 200 9-0-9∗1day 4-0-4∗7day TAB. Rebex D 1-0-0 CAP.D3 HD 1-0-0(Once) TAB. Vit A 1-0-0 TAB. Vit C 500 1-0-1 TAB. A-Z Gold 1-0-0 Inj. Clexane 1-0-0 TAB. Cettas 200 1-0-1 | Cough | |
| 2/8/2020 | Inj. Remdesevir 100 mg OD Inj. Durataz 4.5 mg in 100NS TDS Inj. Rabicip 20 mg OD Inj. Ondem 4 mg TDS Inj. Dexa 4 mg TDS Inj. Clexane 0.6 OD TAB. Colchicine 100 mg BD TAB. Viznil HS TAB. Bandy plus BD SYP. Ascoril 2 Tsp TDS NS/RL 8hrly
| Cough | |
| 3/8/2020 | Inj. Remdesevir 100 mg OD Inj. Durataz 4.5 mg in 100NS TDS Inj. Rabicip 20 mg OD Inj. Ondem 4 mg TDS Inj. Dexa 4 mg TDS Inj. Clexane 0.6 OD TAB. Chalchicine 100 mg BD TAB. Viznil HS TAB. Bandy plus BD SYP. Ascoril 2 Tsp TDS NS/RL 8hrly
| Cough | |
| 4/8/2020 | Inj. Remdesevir 100 mg OD Inj. Durataz 4.5 mg in 100NS TDS Inj. Rabicip 20 mg OD Inj. Ondem 4 mg TDS Inj. Dexa 4 mg TDS Inj. Clexane 0.6 OD TAB Chalchicine 100 mg BD TAB Viznil HS TAB Bandy plus BD SYP Ascoril 2 Tsp TDS NS/RL 8hrly | Cough | |
| 5/8/2020 | Inj. Remdesevir 100 mg OD Inj. Durataz 4.5 mg in 100NS TDS Inj. Rabicip 20 mg OD Inj. Ondem 4 mg TDS Inj. Dexa 4 mg TDS Inj. Clexane 0.6 OD TAB Chalchicine 100 mg BD TAB Viznil HS TAB Bandy plus BD | Sunthi + Kantakari + Pushkarmul + Guduchi each 20 gm + Rasa Sindur 1 gm (21 packets) 1 packet with warm water tds | Cough |
| 6/8/2020 | Cough | ||
| 7/8/2020 | Inj. Durataz 4.5 mg in 100NS TDS Inj. Rabicip 20 mg OD Inj. Ondem 4 mg TDS Inj. Dexa 4 mg TDS Inj. Clexane 0.6 OD TAB Chalchicine 100 mg BD TAB Viznil HS TAB Bandy plus BD SYP Ascoril 2 Tsp TDS NS/RL 8hrly | Cough | |
| 8/8/2020 | Inj. Durataz 4.5 mg in 100NS TDS Inj. Rabicip 20 mg OD Inj. Ondem 4 mg TDS Inj. Dexa 4 mg TDS Inj. Clexane 0.6 OD TAB Chalchicine 100 mg BD TAB Viznil HS TAB Bandy plus BD SYP Ascoril 2 Tsp TDS NS/RL 8hrly | Cough | |
| 9/8/2020 | Inj. Durataz 4.5 mg in 100NS TDS Inj. Rabicip 20 mg OD Inj. Ondem 4 mg TDS Inj. Dexa 4 mg TDS Inj. Clexane 0.6 OD TAB Chalchicine 100 mg BD TAB Viznil HS TAB Bandy plus BD SYP Ascoril 2 Tsp TDS NS/RL 8hrly | Cough | |
| 10/8/2020 | TAB Omnix 200 mg BD TAB Drego D OD TAB Doxovent 200 mg BD TAB Wysolone 20 mg OD TAB Goutnil 0.5 mg HS TAB Supra plus OD TAB Viznil HS | Cough mouth ulcer | |
| 11/8/2020 | TAB Omnix 200 mg BD TAB Drego D OD TAB Doxovent 200 mg BD TAB Wysolone 20 mg OD TAB Goutnil 0.5 mg HS TAB Supra plus OD TAB Viznil HS | Cough mild and mouth ulcer |
Investigations.
| Coombs test (24/5/2020) | Negative for complete antibodies at 37.5 °C | ||
| Negative for incomplete antibodies at37.5 °C | |||
| Bone marrow biopsy (25/5/2020) | Bone marrow shows compensatory response to anaemia with features of Vitamin B12/folic acid deficiency. No definite evidence of malignancy | ||
| Folic acid (27/5/2020) | 5.49 ng/ml | ||
| Abnormal haemoglobin Studies (25/5/2020) | |||
| Fetal Haemoglobin | 0.5 | Suggestive of beta thalassemia trait. | |
| Haemoglobin A O | 95.2 | ||
| Haemoglobin A2 | 5.3 | ||
| Reticulocyte | 2.6 | ||
| 28/5/2020) USG Abdomen and pelvis | Mild splenomegaly is noted without any focal lesion. | ||
| Cholelithiasis without changes of cholecystitis | |||
| Mild hepatomegaly with grade II fatty infiltration of the liver | |||
| Gaseous distension and dilatation of the entire colon. | |||
| 26/7/2020 RTPCR Covid | Positive | ||
| 2/8/2020 | 4/8/2020 | 23/8/2020 | |
| Haemoglobin | 8.6 gm/dl | 8.3 gm/dl | |
| HCT | 31.8% | 30.2% | |
| MCV | 65.2 fl | 65 fl | |
| MCH | 17.5% pg | 17% pg | |
| MCHC | 26.9 gm/dl | 27.3 gm/dl | |
| RDW-CV | 0.136 | 0.136 | |
| RDW-SD | 37.2 fl | 37.1 fl | |
| RBC | 4.87 × 106/uL | 4.65 × 106/uL | |
| WBC | 6.18 × 103/uL | 2.83 × 103/uL | |
| Neutrophil | 0.883 | 0.536 | |
| Lymphocytes | 0.082 | 0.261 | |
| Monocytes | 0.033 | 0.120 | |
| Eosinophil | 0.001 | 0.080 | |
| Basophils | 0.001 | 0.003 | |
| Platelet count | 203 × 103 u/L | 162 × 103 u/L | |
| CRP | 36.2 mg/dl | 3 mg/dl | |
| D-Dimer | 309 ng/ml | 204.27 ng/ml | 167.65 ng/ml |
| S. Sodium | 134.1 mEq/L | 139 mEq/L | |
| S.Potassium | 4.11 mEq/L | 3.64 mEq/L | |
| S.Chloride | 108 mEq/L | 110.3 mEq/L | |
| Total bilirubin | 0.83 mg/dl | ||
| Direct Bilirubin | 0.33 mg/dl | ||
| Indirect Bilirubin | 0.50 mg/dl | ||
| SGOT | 48IU/L | ||
| SGPT | 43IU/L | ||
| S. Alkaline Phosphatase | 209 | ||
| Creatinine | 1.16 mg|dl | ||
| UREA | 43 mg/dl | ||
| SLDH | 583IU/L | ||
| Sr. ferritin | 886.45 ng/ml | ||
| CT THORAX | |||
| 26/7/2020 | 5/8/2020 | 23/8/2020 | |
| Subtle patchy ground glass opacities in Right lower lobe s|o alveolar infiltrate, however early changes of Covid-19 inf. Cannot rule out (CORADS3) | Atypical organizing pneumonia | No Significant abnormality in present study | |
| Comment:- Swab testing RT PCR And Follow CT Thorax would help | Quality for CORADS-5 and CT severity score 7 (mild infection) | ||
Ayurvedic properties of medicines used.
| Medicine | Properties | Action |
|---|---|---|
| Used in | ||
| Used in |
Graph 2Score of symptoms of proper digestion, Capacity to eat, Appetite.